927 results on '"van de Loosdrecht, Arjan A."'
Search Results
2. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia
3. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
4. Dysregulation of developmental and cell type-specific expression of glycoconjugates on hematopoietic cells: a new characteristic of myelodysplastic neoplasms (MDS)
5. Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression
6. Molecular taxonomy of myelodysplastic syndromes and its clinical implications
7. Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
8. Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort study
9. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
10. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
11. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
12. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling
13. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
14. Management of patients with lower-risk myelodysplastic syndromes
15. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
16. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something
17. Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
18. Guideline-based indicators for adult patients with myelodysplastic syndromes
19. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
20. Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
21. Morphology and Flow Cytometry
22. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
23. Can we incorporate MRD assessment into clinical practice in AML?
24. TCF4 promotes erythroid development
25. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands
26. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
27. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning
28. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE
29. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
30. P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
31. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
32. Active Specific Immunization by the Use of Leukemic Dendritic Cell Vaccines
33. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
34. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
35. Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes
36. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
37. Challenging the status flow: how artificial intelligence is advancing diagnosis of myelodysplastic neoplasms
38. Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes
39. Supplementary Table Legend from MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage as Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia
40. Supplementary Figure 1 from Absence of Class II–Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells
41. Data from Absence of Class II–Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells
42. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
43. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
44. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?
45. Diagnostic algorithm for lower-risk myelodysplastic syndromes
46. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
47. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
48. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues
49. Time-dependent changes in mortality and transformation risk in MDS
50. Morphology and Flow Cytometry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.